MARKET

PRTA

PRTA

Prothena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.01
-0.29
-1.10%
After Hours: 26.01 0 0.00% 16:01 05/16 EDT
OPEN
26.03
PREV CLOSE
26.30
HIGH
26.67
LOW
25.16
VOLUME
505.04K
TURNOVER
0
52 WEEK HIGH
79.75
52 WEEK LOW
22.11
MARKET CAP
1.22B
P/E (TTM)
21.18
1D
5D
1M
3M
1Y
5Y
These Analysts Just Made A Massive Downgrade To Their Prothena Corporation plc (NASDAQ:PRTA) EPS Forecasts
Today is shaping up negative for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...
Simply Wall St. · 05/08 12:02
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Zacks · 05/06 16:24
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:35
Prothena Corp Q1 Net Loss $36.3M, Sales $1.20M Miss $8.08M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly sales of $1.20 million which missed the analyst consensus estimate of $8.08 million by 85.15 percent. This is a 650.00 percent increase over sales of $160.00 thousand the
Benzinga · 05/05 22:09
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 millionAdvanced PRX012, a potential best-in-class, subcutaneous treatment for Alzheimer’s disease, into a P...
GlobeNewswire · 05/05 20:05
-- Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $1.2M
MT Newswires · 05/05 17:10
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
Prothena Q1 2022 Earnings Preview
Prothena (NASDAQ:PRTA) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is -$0.64 (+29.7% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/04 21:35
More
No Data
Learn about the latest financial forecast of PRTA. Analyze the recent business situations of Prothena through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
50.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRTA stock price target is 69.67 with a high estimate of 100.00 and a low estimate of 45.00.
High100.00
Average69.67
Low45.00
Current 26.01
EPS
Actual
Estimate
-0.050.671.402.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 254
Institutional Holdings: 45.28M
% Owned: 96.74%
Shares Outstanding: 46.81M
TypeInstitutionsShares
Increased
72
2.66M
New
41
946.70K
Decreased
36
950.90K
Sold Out
35
705.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
Gene Kinney
Chief Financial Officer
Tran Nguyen
Chief Operating Officer
Brandon Smith
Chief Accounting Officer
Karin Walker
Chief Scientific Officer
Wagner Zago
Other
Hideki Garren
Other
Carol Karp
Other
Radhika Tripuraneni
Secretary
Michael Malecek
Independent Director
Paula Cobb
Independent Director
Richard Collier
Independent Director
Shane Cooke
Independent Director
K. Anders Harfstrand
Independent Director
Christopher Henney
Independent Director
Oleg Nodelman
Independent Director
Sanjiv Patel
Independent Director
Dennis Selkoe
No Data
No Data
About PRTA
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.